The Africa Centres for Disease Control and Prevention (Africa CDC) announced Monday that the latest Ebola outbreak in Africa has claimed 5,376 lives, with 5,372 deaths occurring in the Democratic Republic of the Congo (DRC). The outbreak, declared in mid‑May, is the 17th and the largest Ebola episode the DRC has faced to date.
Scope of the outbreak
The Bundibugyo strain of Ebola, which drives the current crisis, has infected a total of 10,444 individuals across the DRC, Uganda and Kenya. The strain’s case‑fatality rate exceeds 50 percent, making it one of the deadliest forms of the virus. While the DRC accounts for the overwhelming majority of both cases and deaths, the outbreak has also claimed two lives each in Kenya and Uganda.
Cross‑border spread
In recent months the virus has crossed international borders on several occasions. Uganda recorded 20 cases, almost all linked to travelers from the DRC, before being declared Ebola‑free in August. Kenya reported its first recorded Ebola cases in October, with nine infections and two deaths. Nigeria conducted two rounds of testing on suspected cases in its northeast region; both samples tested negative, and the country’s capital, Abuja, logged its first imported case in October, the first in more than a decade, without any associated deaths. France reported a single case involving a health worker who returned from the DRC in July.
Regional responses
Health authorities across the affected nations have responded with heightened surveillance, testing and isolation measures. Uganda’s swift containment allowed it to clear its case count by August. Kenya’s health ministry documented the October infections and deaths, marking a historic entry of Ebola into the country. Nigeria’s negative test results and lack of fatalities underscore the effectiveness of its early detection protocols. In France, the isolated case among a returning health worker prompted targeted monitoring but did not lead to broader transmission.
Vaccine and treatment outlook
There are currently no approved treatments or vaccines specifically targeting the Bundibugyo strain. However, clinical trials have recently begun using the Ervebo vaccine, which has demonstrated efficacy against the more common Zaire strain of Ebola. The initiation of these trials reflects an effort to expand protective options, though no definitive solution is yet available for the Bundibugyo variant.
The continuing high mortality and cross‑border spread highlight the urgent need for coordinated regional action, accelerated research on strain‑specific interventions, and sustained public‑health vigilance across Central and East Africa.
Helene Elliott is the Lead Science & Space Reporter at News Raise. She reports on aerospace missions, astrophysics discoveries, quantum research, and environmental technology.
